Tritonix.ai

News / Taiwan / economic_daily

FTSE Russell Announces Taiwan Index Rebalancing: PharmaEssentia In, Alchip Out

Health Technology · Biotechnology · economic_daily · 2026-09-04

1301, 2371, 2379, 2441, 2615, 2637, 2845, 2855, 3006, 3189, 3406, 3450, 3481, 3661, 4583, 4919, 6005, 6446, 6944, 6949, 7610, 8039, 8454

FTSE Russell has unveiled its latest quarterly index review for Taiwan, with PharmaEssentia joining the Taiwan 50 Index while Alchip-KY is removed.

What Happened

Index Rebalancing: FTSE Russell has released its latest quarterly review for Taiwan indices, featuring significant changes to the Taiwan 50 Index. PharmaEssentia will be added to the index, while Alchip-KY will be removed, with changes taking effect after the market close on September 18, 2026.

Mid-Cap and Tech Indices: The Taiwan Mid-Cap 100 Index will see the addition of Alchip-KY and Elite Semiconductor Microelectronics, while Taiwan Elite Material is removed. Simultaneously, the Taiwan Information Technology Index will add Elite Semiconductor Microelectronics and drop Nuvoton Technology.

Broad Market and Dividend Indices: The Taiwan Developed Index will include additions such as Lianyu Metal and Peil Biomedical, while removing Taiwan Elite Material and Tatung. The Taiwan High Dividend Index remains unchanged for this cycle, though it will undergo a five-day transition period for weight adjustments starting September 21.

Implementation and Reserves: The adjustments are scheduled to take effect on September 21, 2026. In the event of any interim deletions, the indices will utilize their respective reserve lists, which currently include Formosa Plastics for the Taiwan 50 Index and Capital Securities for the Mid-Cap 100 Index.

Read original

More in Health Technology

Skylabs Soars 135% on KOSDAQ Debut

Health Technology · yonhap_finance · 2026-09-04

Medical device manufacturer Skylabs closed its first day of trading on the KOSDAQ up 135% from its IPO price, marking a successful market entry.

386380

Han-Kang's Subsidiary Files IND with FDA for Novel Tri-specific Immunotherapy HCB303

Health Technology · cnyes · 2026-09-04

Han-Kang-KY's subsidiary, FBD Biologics, has submitted an IND application to the FDA for HCB303, a tri-specific immunotherapy targeting advanced solid tumors.

7827

AJ Biologics Files for Phase 3 Clinical Trial of SBMA Drug with US FDA

Health Technology · cnyes · 2026-09-04

AJ Biologics has submitted a Phase 3 clinical trial application to the FDA for its SBMA treatment, AJ201, aiming for a Q4 launch to bolster its global licensing potential.

7754

Latest in Taiwan

Taiwan Stocks Surge 693 Points as Institutional Investors Return to Market

Electronic Technology · economic_daily · 2026-09-04

Taiwan's stock market rebounded strongly on Friday, with institutional investors net buying over NT$62 billion, led by gains in AI and passive component sectors.

00631, 00685, 2308, 2317, 2324, 2327, 2330, 2356, 2382, 2408, 2409, 2454, 2472, 2478, 2492, 3026, 3037, 3090, 3231, 3624, 3711, 6173, 6669, 8042

Institutional Investors Pour Over NT$62.8 Billion into Taiwan Stocks

Finance · economic_daily · 2026-09-04

Taiwan stocks surged today, closing up 693.47 points with a total turnover of NT$825.6 billion, as institutional investors collectively net bought NT$62.87 billion.

Topoint Technology August Revenue Hits Record High, YTD Figures Surpass Full-Year 2025

Electronic Technology · cnyes · 2026-09-04

PCB drill bit manufacturer Topoint Technology reports record-breaking August revenue, with year-to-date performance already exceeding the total for 2025.

6026, 8021

TWSE to Lead Delegation to London to Boost Global Capital Market Ties

Finance · economic_daily · 2026-09-04

TWSE Chairman Lin Shyh-ming will lead a delegation to London in September to promote Taiwan's capital market, attract foreign investment, and foster global ties.